Related Experiment Video

Updated: May 26, 2026

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

Oncogene-targeting T cells reject large tumors while oncogene inactivation selects escape variants in mouse models of

Kathleen Anders1, Christian Buschow, Andreas Herrmann

  • 1Max-Delbrück-Center for Molecular Medicine, Berlin, Germany.

Cancer Cell
|December 17, 2011
PubMed

Insights

Cancer cells develop drug resistance due to genetic instability. T-cell therapy effectively eliminated large tumors by destroying vasculature and bystander cells, unlike drug treatments that selected for resistant clones.

Area of Science:

  • Oncology
  • Immunology
  • Cancer Genetics

Background:

  • Genetic instability in cancer cells is a primary driver of therapeutic resistance.
  • Conventional drug therapies often face limitations in overcoming acquired resistance in large tumors.

Purpose of the Study:

  • To compare the efficacy of drug-mediated oncogene inactivation versus CD8(+) effector T (T(E)) cell therapy in mouse cancer models with genetic instability.
  • To investigate the mechanisms underlying tumor rejection and resistance development under different treatment modalities.

Main Methods:

  • Establishment of mouse cancer models with genetically unstable tumors.
  • Targeting of oncogenes using drug-mediated inactivation.
  • Treatment with monospecific CD8(+) effector T (T(E)) cells.
  • Assessment of tumor rejection, clone selection, and vascular integrity.

Main Results:

  • Drug treatment initially reduced large tumors but led to the long-term selection of resistant clones.
  • T(E) cell therapy achieved complete rejection of large tumors (≥500 mm(3)) when targeting a cancer-driving antigen.
  • T(E) cell treatment resulted in tumor vasculature destruction and potential bystander elimination of resistant variants, unlike drug therapy.

Conclusions:

  • CD8(+) effector T (T(E)) cell therapy offers a superior strategy for eradicating genetically unstable, drug-resistant tumors compared to conventional drug-mediated oncogene inactivation.
  • The destruction of tumor vasculature and bystander elimination by T(E) cells are critical mechanisms for overcoming therapeutic resistance and preventing tumor recurrence.

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

Related Concept Videos

Mouse Models of Cancer Study02:43

Mouse Models of Cancer Study

Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
Mouse Models of Cancer Study02:43

Mouse Models of Cancer Study

Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
In-vitro Mutagenesis01:16

In-vitro Mutagenesis

To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...